What is the feedback from patients after using Vorasidenib?

Vorasidenib (Vorasidenib) is an oral targeted drug targeting IDH mutations, and the feedback from patients after using it is generally positive. Most patients report that the drug is well tolerated and has mild side effects. Common minor discomforts include fatigue and gastrointestinal reactions. Many patients can maintain a good quality of life in daily life without symptoms that significantly affect their work and life.

However, some patients experience side effects that require concern, such as elevated liver enzymes and electrolyte imbalances. For example, some patients experienced abnormal liver function indicators in the early stages of taking the drug, but the symptoms were relieved after a short period of discontinuation of the drug or adjustment of the dose. This suggests that regular monitoring of liver function and electrolyte levels is very important during treatment. Timely detection of abnormalities can effectively avoid serious adverse reactions.

In addition, a small number of patients reported mild neurological symptoms, such as short-term memory loss, dizziness and even occasional epileptic seizures. Although such symptoms are uncommon, patients and doctors need to remain vigilant and take auxiliary treatment or adjust medication regimens when necessary to ensure treatment safety.

In terms of efficacy, patients generally reported that vorsidenib has a better effect on tumor control. After several months of treatment, imaging examinations of some patients show that the tumor size has stabilized or shrunk, and clinical symptoms have improved. Combined with clinical studies, vorsidenib can significantly extend progression-free survival, bringing new hope to patients. In short, vorsidenib has shown good safety and efficacy in clinical use and is an important treatment option for patients with IDH mutation-related tumors.

Reference materials:https://www.drugs.com/